Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
We’ve got a new site launch, local IPOs, and much more to dig through in this week’s roundup. But first, a programming note to you Xconomy readers: I’ll be away on... Read more »
Catabasis Pharmaceuticals has done some strategic tinkering over the past few years, and the Cambridge, MA-based company did a bit more maneuvering on Wednesday to price its IPO.
Catabasis is set... Read more »
Back in March, Epizyme regained most of the rights to a drug it’s been developing for a wide array of cancers. There’s still a long way to go, but the move... Read more »
It’s been a jam-packed few months for Flagship Ventures, one of the Boston area’s most well-known biotech startup creators.
If microchip systems that act like organs are ever going to really change preclinical drug development, it’s going to happen one experiment—and Big Pharma adopter—at a time. Emulate is trying to... Read more »
Aerie Pharmaceuticals took a big step back earlier this year when its glaucoma drug came up short in the first of a few Phase 3 trials. But the Bedminster, NJ-based company... Read more »
In a friendly IPO market for biotechs, going public the other way—reverse merging with a shell company—is understandably the path less trodden. But after a strategic reinvention, it was the best... Read more »
New startups. New data. Financings. Acquisitions. Legal tussles. FDA advisory panels. It’s been that kind of week in East Coast biotech. So grab some coffee and let’s roll through this week’s... Read more »
Accelerate Long Island’s main mission has been to turn the science at its nearby research institutions into full-fledged companies with venture investors of their own. With a small funding round being... Read more »
It’s been quite a week for Unum Therapeutics. Just three days after inking its first partnership, the emerging cellular immunotherapy startup has bagged its biggest funding round to date, and an... Read more »
Call it ground zero in a patient’s battle with cancer: the tumor microenvironment, the tissue around a cancerous cell that gets tricked into doing its bidding. That critical terrain is becoming... Read more »
Take a poll of most of biotech’s venture capitalists—the ones that survived the financial crash, anyway—and you might find that just about all of them have reloaded with new funds over... Read more »
Unum Therapeutics started up last year with its own twist on the increasingly crowded field of cellular immunotherapy. Today, that plan got a stamp of support from Seattle Genetics.
SeaGen (NASDAQ:... Read more »
It’s no secret that there’s a huge need for more effective antibiotics. The number of bacteria evolving and evading current treatments continues to grow, and government agencies are trying to lend... Read more »
Vertex Pharmaceuticals has reshaped itself into a cystic fibrosis powerhouse the past few years. Today, it’s trying to add to that position by teaming up with a biotech out of Durham,... Read more »
The immuno-oncology field is moving fast these days, but the tough-to-treat blood cancer multiple myeloma has not been one of its early targets. Biotech partners Bluebird Bio and Celgene would like... Read more »
Celldex Therapeutics grabbed the spotlight late last year when an experimental vaccine it’s been developing helped extend the lives of some patients with an aggressive, deadly form of brain cancer. In... Read more »
Call it the calm before the storm. All eyes in biotech this weekend will turn to the year’s big cancer meeting, the American Society of Clinical Oncology’s annual bash in Chicago.... Read more »
Pronutria looks a little different today than the startup that emerged from stealth in 2013. It’s added “Biosciences” to the end of its name to reflect a shift in strategy. Its... Read more »
Former CEO, Infectious Disease Research Institute and Targeted Genetics
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.